Akari Therapeutics Plc (AKTX): Going concern doubt
Severity scores the disclosed filing signal, not a judgment about the company or its securities.
What was disclosed
not sufficient to fund its operations for the one-year period after the date these condensed consolidated financial statements are issued. These factors raise substantial doubt about the Company’s ability to continue as a going concern for at least a one-year period following the issuance of these condensed consolidated financial statements.
Why it matters
A going-concern disclosure reflects substantial doubt about the company's ability to continue operating.